Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore.
Ahead of CapMan's Q3 2025 results on 6 November, we only make minor revisions to our adjusted EBIT e...
Insplorion has signed an LoI with Mann Tek, a major manufacturer of couplings for fluids and gases.
* Seasonally weaker volumes to weigh on earnings * 10-12% '26e-'27e sales growth, 21-22% EBIT margin...
Redeye comments on Active Biotech’s proposed fully guaranteed rights issue of SEK70m, which is large...
* Q3 softer due to sizeable customer trimming '25 volumes * '25e-'27e sales cut by 11-6% and '26e-'2...
We maintain our estimates intact ahead of Relais Q3 report.
Redeye provides an initial take following Q-linea’s Q3 2025 report.
* Q3 sales lower than expected (-5% vs. ABGSCe) * Major untapped potential in Recycling * Long-term ...
Redeye updates its estimates and fair value range following Waystream’s Q3 report.
Following the positive profit warning on 13 October, we nudge up our 2025-27 estimates by 3-5%.
* Q3 report due on 23 October * We cut 2025e EBITA by 3% but raise 2026e-2027e by 3-2% * Share is tr...
* Q3 report due 23 October; we cut '25e-'27e EPS by ~2% * We expect further margin and cash flow rec...
Redeye provides a short comment on GB-A negative decision relating to reimbursement on the German ma...
Redeye adjusts its fair value range following the announcement of the rights issue.
Stabila utdelningar eller fallande trend? Redeye tittar närmare på bolagets utdelningar.
* Sales -5%, adj. EBIT SEK -2m vs. ABGSCe * Seasonal effects impacted Aesthetics segment * Recycling...
Q4 results were broadly in line with expectations, though regional performance diverged from our for...
Sales -18% vs. ABGSCe, EBIT SEK 11m vs. ABGSCe 16m* Newbuild market down 50% y-o-y, affecting growth...
Redeye considers I-Tech’s Q3 figures relatively soft, missing our top-line estimate by 10% and EBITD...
